Compare BBNX & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BBNX | NGNE |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | 423 | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.1M | 498.2M |
| IPO Year | N/A | 2014 |
| Metric | BBNX | NGNE |
|---|---|---|
| Price | $16.49 | $35.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 7 |
| Target Price | $23.80 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 1.1M | 233.2K |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $34.90 | N/A |
| Revenue Next Year | $34.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.80 | $15.93 |
| 52 Week High | $32.71 | $37.27 |
| Indicator | BBNX | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 65.40 | 68.81 |
| Support Level | $16.02 | $19.27 |
| Resistance Level | $32.52 | $36.37 |
| Average True Range (ATR) | 1.07 | 2.05 |
| MACD | 0.14 | 0.39 |
| Stochastic Oscillator | 83.89 | 95.22 |
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.